TERMINATEDNA

Leflunomide Treatment for MEN1 Patients - the LUMEN1 Trial

NCT05605587•University Hospital, Basel, Switzerland

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

MEN1 Gene Mutation

Interventions

Leflunomide 20 mg

Locations

1

Switzerland

Locations (1)

Unispital Basel

Basel, Switzerland

Key Dates

Start Date

May 2, 2023

Primary Completion Date

January 13, 2026

Completion Date

January 13, 2026

Last Updated

January 27, 2026

Sponsors

Lead Sponsor

University Hospital, Basel, Switzerland

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 27, 2026Data synced to Clareo: April 27, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions